期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PI3K/AKT通路在肺癌转移和耐药中的研究 被引量：21

The Study of PI3K/AKT Pathway in Lung Cancer Metastasis and Drug Resistance
下载PDF
导出
摘要 磷脂酰肌醇-3-激酶/丝苏氨酸蛋白激酶(phosphatidyl-inositol 3-kinase/serine-threonine kinase,PI3K/AKT)信号通路是细胞内重要信号转导通路之一,通过影响下游多种效应分子的活化状态,在细胞内发挥抑制凋亡、促进增殖的关键作用,与人类多种肿瘤的发生发展密切相关。研究表明PI3K/AKT信号通路在恶性肿瘤细胞的增殖、血管新生和转移及对放化疗的拮抗中都起着重要作用。对PI3K/AKT信号通路的深入研究有望找到肿瘤预防和药物治疗的新靶点。本文简要介绍了PI3K/AKT信号通路的组成与功能调节,并着重阐述了其在肺癌转移和耐药中的作用。 PI3K/AKT signal pathway is an important intracellular signal transduction pathway.It plays important roles in cell apoptosis and survival by affecting the activity of downstream effector molecules,and it is closely associated with the development and progression of human tumors.Recent researches of PI3K/AKT indicate that this pathway plays important roles in tumor cells proliferation,blood vessel neogenesis,tumor metastasis and resistance to chemotherapy and radiotherapy.The profound research of PI3K/AKT is beneficial to the prevention of tumor and to the finding of potential targets for new drugs.This article reviewed the composition,function and regulation of PI3K/AKT signal pathway,and its effect in metastasis and drug resistance of lung cancer.
作者 祝冰晶 周向东
机构地区 第三军医大学研究生六队 西南医院呼吸内科
出处 《中国肺癌杂志》 CAS 2011年第8期689-694,共6页 Chinese Journal of Lung Cancer
基金 国家自然科学基金(No.30971308)资助~~
关键词 PI3K/AKT 信号转导 肿瘤转移 耐药 肺肿瘤 PI3K/AKT Signal transduction Tumor metastasis Drug resistance Lung neoplasms
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献51

  • 1Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signaling controls tumor cell growth. Nature, 2006, 441 (7092): 424-430.
  • 2Pisick E,Jagadeesh S, Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. Sci World J, 2004, 4: 589-604.
  • 3Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004, 304(5670): 554.
  • 4Hartmann W, Digon-Sontgerath B, Koch A, et al. Phosphatidrl inositol 3'-ki- nase/AKT signaling is actived in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Cli Cancer Res, 2006, 12 (10): 3019-3027.
  • 5Engelmann JA. Targeting PI3K signaling in cancer: opportunities, challenges and limitations. Nat Rev Cancer, 2009, 9(8): 550-562.
  • 6Franke TF. PI3K/Akt: getting it right matters. Oncogene, 2008, 27(50): 6473-6488.
  • 7Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene, 2008, 27(41): 5497-5510.
  • 8Sheng SJ, Ojao M, Pardee AB. Metastasis and AKT activation. J Cell Physiol, 2009, 218(3): 451-454.
  • 9Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signaling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets, 2008, 8(3): 187-198.
  • 10Tokunaga E, Oki E, Egashira A, et al. Deregulation of the Akt pathway in hu- man cancer. Curr Cancer Drug Targets, 2008, 8 (1): 27-36.

二级参考文献81

  • 1张超,杨娜,章雄文,丁健.靶向PI3K-Akt-mTOR信号通路抑制剂的研究进展[J].中国癌症杂志,2006,16(12):1064-1070. 被引量：22
  • 2ZHANG Yu-hua,WEI Wei,XU Hao,WANG Yan-yan,WU Wen-xi.Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways[J].Chinese Medical Journal,2007(9):743-748. 被引量：13
  • 3Le Chevalier T. For the IAL T Investigators. Result s of the Randomized International Adjuvant Lung Cancer Trial ( IAL T) : cisplatin -based chemotherapy (CT) vs no CT in 1867 patient s (pts) with resected non -small cell lung cancer (NSCLC) [ J]. Proc Am Soc Clin Oncol,2003,23:6a.
  • 4Winton TL, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine and cisplatin in completely resected stage Ⅰb and Ⅱ non -small cell lung cancer[ C]. New Orleans 40th Annal Meeting of the American Society of Clinical Oncology,2004,7018.
  • 5Strauss GM, Hemdon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resected in stage Ⅰb non - small cell lung cancer ( NSCLC ) : report of Cancer and Leukemia Group B ( CALGB ) protocol 9633 [ J]. J Clin Oncol,2004,22 ( Suppl 14S) : 612.
  • 6Douillard JY, Rosell R, Delena M, et al. Phase Ⅲ adjuvant vinorelbine and cisplatin versus observation in completely resected ( stage Ⅰ - Ⅲ ) non - small cell lung cancer patients: final results after 70 - month median followup [ J ]. J Clin Oncol, 2005,23 ( Suppl 16s) : 624.
  • 7Pisters K , Vallieres E, Bunn PA, et al. Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin(PC) chemotherapy in early stage non- small cell lung cancer (NSCLC) :Follow -up on a phase Ⅲ trial [ J]. J Clin Oncol,2007.25 (18s) :7520.
  • 8Scagliotti G, Pastorino U, Vansteenkiste J, et al. A phase Ⅲ randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early - stage non - small cell lung cancer (NSCLC) : Follow - up data of Ch.E. S. T [ J ]. J Clin Oncol, 2008,26:7508.
  • 9Nieolson M, Gilligan D, Smith I, et al. Pre - operative chemotherapy in patients with resectable non - small cell lung cancer (NSCLC) : First results of the MRC LU22/NVALT/EORTC 08012 multi - centre randomised trial [ J ]. J Clin Oncal, 2007, 25 (18suppl) : 7518.
  • 10Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non - small cell lung cancer [J]. N Engl J ned,2002,346:92 -98.

共引文献79

同被引文献169

引证文献21

二级引证文献123

中国肺癌杂志
2011年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部